Trevi Therapeutics, Inc. 8-K

What Happened
Trevi Therapeutics, Inc. (TRVI) announced its financial results for the quarter and year ended December 31, 2025 and furnished a press release in connection with the announcement. The company filed a Current Report on Form 8‑K on March 17, 2026 under Item 2.02 (Results of Operations and Financial Condition). The press release is included as Exhibit 99.1 to the 8‑K (furnished, not filed).

Key Details

• Filing date: March 17, 2026 (Form 8‑K reporting results for the quarter and year ended December 31, 2025).
• Press release: Exhibit 99.1 furnished with the Form 8‑K (the exhibit is furnished, not filed).
• Technical filing item: Item 2.02 (Results of Operations and Financial Condition); Item 9.01 lists the exhibit and Inline XBRL cover page (Exhibit 104).
• Authorized signature: Form 8‑K signed by David C. Hastings, Chief Financial Officer of Trevi Therapeutics.

Why It Matters
This 8‑K notifies investors that Trevi has released its latest quarterly and full‑year financial results; the detailed figures (revenue, net income/loss, cash position, and any guidance) will be in the March 17 press release (Exhibit 99.1). Retail investors should read the furnished press release and any accompanying documents (and the company’s subsequent 10‑K or investor presentation, if available) to see the specific financial metrics and assess impacts on the company’s outlook and valuation.